Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) PT at $80.13

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been assigned an average rating of “Buy” from the nine research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $80.13.

A number of research firms have issued reports on ANIP. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a research note on Monday, April 21st. StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 24th. Guggenheim reissued a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, April 11th. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $72.56 on Thursday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $73.72. The firm has a fifty day moving average of $65.96 and a 200-day moving average of $60.41. The company has a market cap of $1.58 billion, a price-to-earnings ratio of -131.93 and a beta of 0.49.

Insider Buying and Selling

In other news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the sale, the senior vice president now directly owns 66,525 shares of the company’s stock, valued at $4,048,711.50. This trade represents a 1.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Meredith Cook sold 400 shares of the business’s stock in a transaction on Monday, April 14th. The stock was sold at an average price of $68.96, for a total value of $27,584.00. Following the sale, the vice president now directly owns 80,145 shares in the company, valued at $5,526,799.20. This trade represents a 0.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock valued at $197,792 over the last three months. Company insiders own 11.10% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC boosted its holdings in shares of ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock worth $8,534,000 after buying an additional 135,003 shares during the period. Franklin Resources Inc. grew its position in ANI Pharmaceuticals by 6.1% during the 3rd quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company’s stock worth $705,000 after purchasing an additional 691 shares in the last quarter. Principal Financial Group Inc. grew its position in ANI Pharmaceuticals by 6.9% during the 3rd quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company’s stock worth $5,367,000 after purchasing an additional 5,829 shares in the last quarter. JPMorgan Chase & Co. raised its stake in ANI Pharmaceuticals by 159.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after purchasing an additional 340,854 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of ANI Pharmaceuticals by 67.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company’s stock valued at $17,226,000 after purchasing an additional 125,438 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.